Skip to Content
Search Menu

WCLC2020: Pembrolizumab significantly improved 5-year survival in patients with previously treated advanced NSCLC

With more than 5 years of follow-up in the Keynote-010 study, pembrolizumab continued to provide clinically meaningful improvement in OS and PFS versus docetaxel in patients with previously treated, PD-L1–positive advanced NSCLC.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Relateret indhold

CheckMate 227: 6-year data on the treatment of locally advanced NSCLC with Opdivo and Yervoy  

/ BestPractice Nordic
NSCLCWCLC23Lung cancer

Adjuvant treatment with 3rd generation EGFR-TKI can increase progression-free survival 

/ BestPractice Nordic
NSCLCWCLC23Lung cancer

WCLC 2023 – NSCLC: New Data on Perioperative Immunotherapy Treatment 

/ BestPractice Nordic
ImmunotherapyNSCLCWCLC23Lung cancer
Tejas Patil

Exceptional response of lorlatinib and cabozantinib combination in ROS1-rearranged NSCLC

/ Tejas Patil
NSCLC Play the Video 07:11
Timothy F. Burns

Osimertinib for the treatment of EGFR-mutant NSCLC in the adjuvant setting

/ Timothy F. Burns
NSCLC Play the Video 10:15
Birgitte Bjørnhart

Real-world studies studies highlight NSCLC data gaps and survival differences from randomized controlled trials

/ Birgitte Bjørnhart
NSCLCDSKO23Lung cancer Play the Video 5:04
Astrid Telhaug Karlsson

Survival rates for patients with NSCLC with brain metastases following whole brain radiotherapy

/ Astrid Telhaug Karlsson
NSCLCELCC23Lung cancer Play the Video 3:22
Niels Reinmuth

Current aspects in early-stage NSCLC – Perspectives from ELCC23

/ Niels Reinmuth
NSCLCELCC23Lung cancer Play the Video 3:54
Siow Ming Lee

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

/ Siow Ming Lee
NSCLCESMO22Lung cancer Play the Video 5:14
Back to top